No Cover Image

Journal article 485 views 117 downloads

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Richard A Chudleigh, Julia Platts, Steve Bain Orcid Logo

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume: 13, Pages: 433 - 438

Swansea University Author: Steve Bain Orcid Logo

  • 53565.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution Non Commercial unported, v3.0 License (CC-BY-NC).

    Download (278.86KB)

Check full text

DOI (Published version): 10.2147/dmso.s193693

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (Q...

Full description

Published in: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
ISSN: 1178-7007
Published: Informa UK Limited 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa53565
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2020-02-20T19:59:26Z
last_indexed 2023-01-11T14:31:11Z
id cronfa53565
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-02T18:56:24.7767254</datestamp><bib-version>v2</bib-version><id>53565</id><entry>2020-02-18</entry><title>Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-02-18</date><deptcode>BMS</deptcode><abstract>Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW &#x201C;long-acting&#x201D; GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness.</abstract><type>Journal Article</type><journal>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</journal><volume>13</volume><journalNumber/><paginationStart>433</paginationStart><paginationEnd>438</paginationEnd><publisher>Informa UK Limited</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>1178-7007</issnElectronic><keywords>GLP-1, type 2 diabetes, cardiovascular trial</keywords><publishedDay>18</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-02-18</publishedDate><doi>10.2147/dmso.s193693</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T18:56:24.7767254</lastEdited><Created>2020-02-18T09:20:25.6197339</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Richard A</firstname><surname>Chudleigh</surname><order>1</order></author><author><firstname>Julia</firstname><surname>Platts</surname><order>2</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>3</order></author></authors><documents><document><filename>53565__16791__777abc3773f443ccb8110983dc87e82b.pdf</filename><originalFilename>53565.pdf</originalFilename><uploaded>2020-03-06T15:30:16.9845713</uploaded><type>Output</type><contentLength>285552</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Released under the terms of a Creative Commons Attribution Non Commercial unported, v3.0 License (CC-BY-NC).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by-nc/3.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-02T18:56:24.7767254 v2 53565 2020-02-18 Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2020-02-18 BMS Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW “long-acting” GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness. Journal Article Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 13 433 438 Informa UK Limited 1178-7007 GLP-1, type 2 diabetes, cardiovascular trial 18 2 2020 2020-02-18 10.2147/dmso.s193693 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-12-02T18:56:24.7767254 2020-02-18T09:20:25.6197339 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Richard A Chudleigh 1 Julia Platts 2 Steve Bain 0000-0001-8519-4964 3 53565__16791__777abc3773f443ccb8110983dc87e82b.pdf 53565.pdf 2020-03-06T15:30:16.9845713 Output 285552 application/pdf Version of Record true Released under the terms of a Creative Commons Attribution Non Commercial unported, v3.0 License (CC-BY-NC). true eng https://creativecommons.org/licenses/by-nc/3.0/
title Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
spellingShingle Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
Steve Bain
title_short Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_full Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_fullStr Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_full_unstemmed Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
title_sort Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Richard A Chudleigh
Julia Platts
Steve Bain
format Journal article
container_title Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
container_volume 13
container_start_page 433
publishDate 2020
institution Swansea University
issn 1178-7007
doi_str_mv 10.2147/dmso.s193693
publisher Informa UK Limited
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW “long-acting” GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness.
published_date 2020-02-18T04:06:34Z
_version_ 1763753480287158272
score 11.013082

Similar Items